How can we improve outcomes after allo-HSCT in patients with AML?

During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the AML Global Portal were delighted to speak to Hee‐Je Kim, The Catholic University of Korea, Seoul, KR. We asked: How can we improve outcomes after allogeneic stem cell transplant in patients with acute myeloid leukemia?

Hee‐Je Kim discusses adult patients with AML that undergo allogeneic stem cell transplantation (allo-HScT), he explains there associated toxicities and complications with allo-HSCT, such as GvHD. He also talks about the importance of using MRD status to monitor response to treatment and relapse. Hee-Je Kim also reports data from trials that investigate antileukemic CTLs in high-risk patients with AML. He concludes by discussing different approaches to lessen GvHD